LEUKAEMIA UK today announced five new John Goldman Fellows for 2021, from across the UK, to accelerate progress and stop the disease devastating lives. Innovators in their fields, each of Leukaemia UK’s John Goldman Fellows will explore a new angle to treating leukaemia over the next two years.
Leukaemia remains one of the deadliest cancers, with an overall UK survival rate of just over 50 per cent (2013-2017). Treatments are harsh and are still lagging behind other cancers in their success rates. Leukaemia is the most common childhood cancer, with it accounting for 33 per cent of all cancers in the under 14s.
Fiona Hazell, Chief Executive of Leukaemia UK, said:
“Whilst blood cancer is the fifth most common cancer in the UK, it remains the third most deadly. Further research is vital to improve survival rates in leukaemia as well as the quality of life for those who receive this devastating diagnosis. Leukaemia UK’s John Goldman Fellowships are novel research projects which will help accelerate progress through the development of much needed new and better treatments for leukaemia and other blood cancers, helping save and improve the lives of those living with the disease.”
Based across the UK in Birmingham, London, Edinburgh, York and Oxford, the new Leukaemia UK John Goldman Fellows are embarking on research projects ranging from looking at how more targeted drugs treatments can be developed to treat acute myeloid leukaemia (AML) patients, to looking at the behaviour of leukaemia-
Leukaemia UK’s John Goldman Fellows for 2021 include:
Dr Daniel Coleman of the University of Birmingham who will be looking at how drugs can be used to target the mutated signalling proteins in the cancerous cells in acute myeloid leukaemia (AML) patients. By targeting mutated RAS genes Dr Coleman hopes to block the pathway for leukaemia cells to grow and will identify further treatment targets to reduce the need for aggressive chemotherapy in vulnerable patients.
Dr Coleman said:
“Acute myeloid leukaemia (AML) is a particularly aggressive blood cancer and most often affects elderly patients. It is frequently difficult to treat with aggressive chemotherapy as patients are often already quite frail. For this reason, it is important to develop treatments which target just the cancer cells and leave the healthy cells intact.”
Dr William Grey of the University of York will be looking at how to attack leukaemic stem cells, the origin of leukaemia and the cells responsible for relapse after treatment, by targeting protein modifications and their breakdown.
Dr Grey said:
“In this fellowship funded by Leukaemia UK, I will investigate specific targeting of leukaemic stem cells, leveraging an Achilles heel in their protein turnover machinery. In combination with newly available medicines, I aim to improve treatment options for the most elderly and at-risk AML patients.”
Dr Samanta Mariani of the University of Edinburgh will be investigating the role of leukaemia-associated immune cells called macrophages in chemotherapy-resistant cells in cases of infant leukaemia. She will look at these macrophages in infant leukaemia to see if they have a significant role in the onset or progression of the disease.
Dr Mariani said:
“Acute leukaemias, the most common in infants and children, are difficult to treat. Chemotherapy is only able to eradicate the disease in half of the infant cases. There is a critical need to understand what happens in the early stages of leukaemia’s development to better target the progression of the disease.”
Dr Giulia Orlando of the University of Oxford will be looking at the changes that RAS genes induce in juvenile myelomonocytic leukaemia to see whether there is the possibility for more targeted treatments to improve patient outcomes.
Dr Orlando said:
“During my John Goldman Fellowship, I will study a rare form of childhood cancer, juvenile myelomonocytic leukaemia (
